Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01150487
Other study ID # 10-002572
Secondary ID R21AI125719
Status Recruiting
Phase N/A
First received
Last updated
Start date October 5, 2010
Est. completion date April 2030

Study information

Verified date June 2024
Source Mayo Clinic
Contact Nong Yowe Braaten
Phone 507-538-9617
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to determine a comprehensive immune profile of transplant donors and recipients through assessment of immune cell compositions in bone marrow, and lymph nodes.


Description:

The aim of this risk protocol is to determine the variability of the AlloElispot and Allospecificities assay. Our group has developed a number of assays to assess the immune cell population in our transplant population. This has included: 1) the number of donor-specific alloantibody (DSA) secreting bone marrow derived plasma cells (AlloELISPOT assay), 2) the function of DSA-secreting Plasma cells (Allospecificities assay), 3)Culture of plasma cells in human stromal cells to produce specific HLA antibodies and tetanus antibodies, 4) Understand the critical pathways for the survival and function of plasma cells, 5)Characterize the different phenotypes and genotypes of the plasma cell, 6)Phenotype analyses of the immune cell population using flow cytometry and/or mass spectrometry (ie. cytometry by time of flight/CyTOF), 7)Functional assessments of T and B-cells, and 8)T-cell receptor diversity. These assays were developed over the years and already have provided an important means of testing new therapeutic protocols aimed at controlling DSA production. It is important to note that repeated attempts to isolate PCs from peripheral blood have been unsuccessful (PCs are extremely rare in peripheral blood) and the bone marrow is the only accessible source of PCs. It is now clear to that we have reached a point that we must validate these assays (coefficient of variation, etc), in order to appropriately evaluate data derived from these assays. Inter-assay variability can be assessed by performing two paired assays in the same patient. This could be done in two ways-paired bone marrow aspirations separated by time or two bone marrow aspirations performed at the same time. We have decided to pursue the latter approach. We will do both marrows either at the time of transplantation or while they are undergoing a surgical procedure. Lymph node retrieval will also be performed at the time for abstraction of immune cells for additional analysis. We believe that this is safe and will be well-tolerated and will provide the data that we need to validate the assays.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date April 2030
Est. primary completion date April 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion criteria. - Pre or post renal transplant recipients. - Renal transplant donors. - Those who give voluntary written informed consent before performance of any study-related procedures, which are not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. Exclusion criteria. - Any patient currently receiving systemic anticoagulation therapy with heparin or coumadin. - Patient has a platelet count of <30 x 10(9)/L within 14 days before enrollment. - Patient has an absolute neutrophil count of ANC<1.0 x 10(9)/L within 14 days before enrollment. - Patient has received other investigational drugs within14 days before enrollment. - Serious medical or psychiatric illness likely to interfere with participation in this clinical study. - Diagnosed or treated for malignancy within 5 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy. - Contraindication to kidney transplantation or donation-active infection, comorbid medical conditions, etc

Study Design


Intervention

Procedure:
bone marrow aspirations
A bone marrow aspiration from each hip bone of the patients.
lymph node collection
An Iliac lymph node collection.

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Mayo Clinic National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine a comprehensive immune profile of transplant donors and recipients through assessment of immune cell compositions in bone marrow, and lymph nodes. 1 week Post bone marrow and lymph node collection.
See also
  Status Clinical Trial Phase
Completed NCT01336296 - Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients Phase 4
Recruiting NCT05938712 - The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients Phase 2
Completed NCT00217100 - A Multivitamin Comparison Study in Kidney Transplant Recipients. Phase 3
Active, not recruiting NCT00199667 - Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients Phase 4
Terminated NCT01517984 - Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation Phase 2
Recruiting NCT04642833 - Prostate Cancer in Renal Transplants Recipients
Not yet recruiting NCT05293704 - An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients Phase 4
Completed NCT02555566 - Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study N/A
Completed NCT01782586 - Validation of Gene Expression Markers of Renal Allograft Functional Decline
Enrolling by invitation NCT02042963 - KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT) N/A
Not yet recruiting NCT05702398 - Pilot Trial of Supplemental Vitamin A and Nicotinamide Early Phase 1
Active, not recruiting NCT05425498 - The Effects of Physical Activity Behavior Change in Kidney Transplant Recipients N/A
Completed NCT01889758 - Pharmacokinetic Studies of Tacrolimus in Transplant Patients Phase 4
Terminated NCT02268201 - A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule Phase 4
Active, not recruiting NCT03979365 - Envarsus XR Compared to Immediate Release Tacrolimus Phase 4
Recruiting NCT04965935 - Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients Phase 3
Recruiting NCT04444843 - Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen Phase 4
Completed NCT02392312 - Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
Completed NCT02639949 - Measuring and Improving Medication Adherence in Kidney Transplant Patients N/A
Withdrawn NCT02058875 - Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring Phase 4